Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD

Journal of Attention Disorders

Volumn 21, Issue 5, 2017, Pages 433-441

  Barragán, Eduardo ^a   Breuer, Dieter ^b   Döpfner, Manfred ^b  

^a The Federico Gómez Children s Hospital of Mexico   (Mexico)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ADHD; children; methylphenidate; nonpharmacological treatment; omega fatty acids

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ATTENTION DEFICIT DISORDER; CHILD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; HUMAN; IMPULSIVENESS; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; MALE; METHYLPHENIDATE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 85014697696     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054713518239     Document Type: Article

References (33)

1. American Academy of Pediatrics. (2000). Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics, 105, 1158-1170.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
4. Barragán-Pérez E., de la Peña-Olvera F., Ortiz-León S., Ruiz-García M., Hernández-Aguilar J., Palacios-Cruz L., Suárez-Reynaga A., (2007). First Latin American consensus statement on attention-deficit hyperactivity disorder. Boletín Médico del Hospital Infantil de México, 64, 326-343.
5. Berger I., Dor T., Nevo Y., Goldzweig G., (2008). Attitudes toward attention-deficit hyperactivity disorder (ADHD) treatment: Parents’ and children’s perspectives. Journal of Child Neurology, 23, 1036-1042.
6. Bloch M. H., Qawasmi A., (2011). Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 50, 991-1000.
7. Buitelaar J. K., Trott G. E., Hofecker M., Waechter S., Berwaerts J., Dejonkheere J., Schäuble B., (2012). Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. International Journal of Neuropsychopharmacology, 15, 1-13.
8. Cohen J., (2013). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum.
9. Colquhoun I., Bunday S., (1981). A lack of essential fatty acids as a possible cause of hyperactivity in children. Medical Hypotheses, 7, 673-679.
10. Conners C. K., Epstein J. N., March J. S., Angold A., Wells K. C., Klaric J... Wigal T., (2001). Multimodal treatment of ADHD in the MTA: An alternative outcome analysis. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 159-167.
11. Döpfner M., (2010). Psychosocial and other non-pharmacological treatments. In Banaschewski T., Coghill D., et al. (Eds.), Attention-deficit hyperactivity disorder and hyperkinetic disorder (pp. 77-90). Oxford, UK: Oxford University Press.
12. Döpfner M., Breuer D., Walter D., Rothenberger A., (2011). An observational study of once-daily modified-release methylphenidate in ADHD: The effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes. European Child & Adolescent Psychiatry, 20(Suppl. 2), S277-S288.
13. Döpfner M., Breuer D., Wille N., Erhart M., Ravens-Sieberer U., & BELLA Study Group. (2008). How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample—Results of the BELLA study. European Child & Adolescent Psychiatry, 17(Suppl. 1), 59-70.
14. DuPaul G. J., Power T. J., Anastopoulos A. D., Reid R., (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretation. New York, NY: Guildford Press.
15. Faraone S. V., Buitelaar J., (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European Child & Adolescent Psychiatry, 19, 353-364.
16. Graham J., Banaschewski T., Buitelaar J., Coghill D., Danckaerts M., Dittmann R. W... Taylor E., (2011). European guidelines on managing adverse effects of medication for ADHD. European Child & Adolescent Psychiatry, 20, 17-37.
17. Johnson M., Ostlund S., Fransson G., Kadesjo B., Gillberg C., (2009). Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: A randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders, 12, 394-401.
18. López F. A., (2006). ADHD: New pharmacological treatments on the horizon. Journal of Developmental & Behavioral Pediatrics, 27, 410-416.
19. Millichap J. G., Yee M. M., (2012). The diet factor in attention-deficit/hyperactivity disorder. Pediatrics, 129, 330-337.
20. MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry, 56, 1073-1086.
21. Newcorn J. H., Kratochvil C. J., Allen A. J., Casat C. D., Ruff D. D., Moore R. J., Michelson D., (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. American Journal of Psychiatry, 165, 721-730.
22. Olfson M., (2004). New options in the pharmacological management of attention-deficit/hyperactivity disorder. American Journal of Managed Care, 10(Suppl. 4), S117-S124.
23. Polanczyk G., de Lima M. S., Horta B. L., Biederman J., Rohde L. A., (2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. American Journal of Psychiatry, 164, 942-948.
24. Richardson A. J., (2006). Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. International Review of Psychiatry, 18, 155-172.
25. Richardson A. J., Montgomery P., (2005). The Oxford-Durham study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics, 115, 1360-1366.
26. Rucklidge J. J., Johnstone J., Kaplan B. J., (2009). Nutrient supplementation approaches in the treatment of ADHD. Expert Review of Neurotherapeutics, 9, 461-476.
27. Schuchardt J. P., Huss M., Stauss-Grabo M., Hahn A., (2010). Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. European Journal of Pediatrics, 169, 149-164.
28. Sinn N., Bryan J., (2007). Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental & Behavioral Pediatrics, 28, 82-91.
29. Sinn N., Bryan J., Wilson C., (2008). Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: A randomised controlled trial. Prostaglandins, Leukotrienes, & Essential Fatty Acids, 78, 311-326.
30. Sonuga-Barke E. J., Brandeis D., Cortese S., Daley D., Ferrin M., Holtmann M... Sergeant J., (2013). Nonpharmacological interventions for ADHD: Systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry, 170, 275-289.
31. Swanson J. M., Kraemer H. C., Hinshaw S. P., Arnold L. E., Conners C. K., Abikoff H. B... Wu M., (2001). Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 168-179.
32. Transler C., Eilander A., Mitchell S., van de Meer N., (2010). The impact of polyunsaturated fatty acids in reducing child attention deficit and hyperactivity disorders. Journal of Attention Disorders, 14, 232-246.
33. Van der Oord S., Prins P. J., Oosterlaan J., Emmelkamp P. M. G., (2008). Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: A meta-analysis. Clinical Psychology Review, 28, 783-800.